Mesothelin-Specific Immune Responses and Targeted Immunotherapy for Mesothelin-Expressing Tumors

被引：1
|
作者：
Einama, Takahiro [1 ,4 ]
Kawamata, Futoshi [1 ]
Kamachi, Hirofumi [1 ]
Nishihara, Hiroshi [2 ]
Homma, Shigenori [1 ]
Matsuzawa, Fumihiko [1 ]
Mizukami, Tatsuzo [1 ]
Konishi, Yuji [1 ]
Kamiyama, Toshiya [1 ]
Yamamoto, Junji [4 ]
Taketomi, Akinobu [1 ]
Todo, Satoru [3 ]
机构：
[1] Hokkaido Univ, Grad Sch Med, Dept Gen Surg, Sapporo, Hokkaido 0608638, Japan
[2] Natl Hosp Org, Hokkaido Canc Ctr, Dept Pathol, Sapporo, Hokkaido 0030804, Japan
[3] St Marys Hosp, Res Inst, Kurume, Fukuoka 8308558, Japan
[4] Natl Def Med Coll, Dept Surg, 3-2 Namiki, Tokorozawa, Saitama 3598513, Japan
来源：
EBIOMEDICINE | 2017年 / 24卷
关键词：
GASTRIC-CANCER; ERC/MESOTHELIN; ADENOCARCINOMA;
D O I：
10.1016/j.ebiom.2017.09.033
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：16 / 17
页数：2
相关论文
共 50 条
  • [1] Control of human mesothelin-expressing tumors by DNA vaccines
    Chang, C-L
    Wu, T-C
    Hung, C-F
    GENE THERAPY, 2007, 14 (16) : 1189 - 1198
  • [2] Mesothelin-targeted second generation CAR-T cells inhibit growth of mesothelin-expressing tumors in vivo
    Ye, Lin
    Lou, Yuqing
    Lu, Liming
    Fan, Xiaohong
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2019, 17 (01) : 739 - 747
  • [3] Control of human mesothelin-expressing tumors by DNA vaccines
    C-L Chang
    T-C Wu
    C-F Hung
    Gene Therapy, 2007, 14 : 1189 - 1198
  • [4] Mesothelin-specific Immune Responses Predict Survival of Patients With Brain Metastasis
    Liu Zhenjiang
    Rao, Martin
    Luo, Xiaohua
    Sandberg, Elisabeth
    Bartek, Jiri, Jr.
    Schoutrop, Esther
    von Landenberg, Anna
    Meng, Qingda
    Valentini, Davide
    Poiret, Thomas
    Sinclair, Georges
    Peredo, Inti-Harvey
    Dodooa, Ernest
    Maeurer, Markus
    EBIOMEDICINE, 2017, 23 : 20 - 24
  • [5] Effective Depletion of Regulatory T Cells Allows the Recruitment of Mesothelin-Specific CD8+ T Cells to the Antitumor Immune Response Against a Mesothelin-Expressing Mouse Pancreatic Adenocarcinoma
    Leao, Ihid C.
    Ganesan, Priya
    Armstrong, Todd D.
    Jaffee, Elizabeth M.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2008, 1 (03): : 228 - 239
  • [6] Characterization of Mesothelin-specific T cell responses in healthy individuals
    Brockstedt, DG
    Hampl, J
    Bahjat, K
    Lutz, E
    Leong, M
    Liu, WQ
    Pardoll, D
    Giedlin, M
    Jaffee, E
    Dubensky, T
    JOURNAL OF IMMUNOTHERAPY, 2005, 28 (06) : 631 - 631
  • [7] Generation and characterization of an ascitogenic mesothelin-expressing tumor model
    Cheng, Wen-Fang
    Hung, Chien-Fu
    Chai, Chee-Yin
    Chen, Chi-An
    Lee, Chien-Nan
    Su, Yi-Ning
    Tseng, Wen-Yih Isaac
    Hsieh, Chang-Yao
    Shih, Ie-Ming
    Wang, Tian-Li
    Wu, T.-C.
    CANCER, 2007, 110 (02) : 420 - 431
  • [8] Mesothelin targeted cancer immunotherapy
    Hassan, Raffit
    Ho, Mitchell
    EUROPEAN JOURNAL OF CANCER, 2008, 44 (01) : 46 - 53
  • [9] Establishment of novel mAb to human ERC/mesothelin useful for study and diagnosis of ERC/mesothelin-expressing cancers
    Ishikawa, Kiyoshi
    Segawa, Tatsuya
    Hagiwara, Yoshiaki
    Maeda, Masahiro
    Abe, Masaaki
    Hino, Okio
    PATHOLOGY INTERNATIONAL, 2009, 59 (03) : 161 - 166
  • [10] Control of mesothelin-expressing ovarian cancer using adoptive transfer of mesothelin peptide-specific CD8+ T cells
    C-F Hung
    Y-C Tsai
    L He
    T-C Wu
    Gene Therapy, 2007, 14 : 921 - 929
12345